Nanogen to Go Commercial With Macdonald | GenomeWeb

David Macdonald’s come a long way from building weapons systems. After his start at Raytheon in his native Boston, he ventured into science and hasn’t left since. Now senior vice president of operations at Nanogen, Macdonald says his job will be “taking the technologies that have been developed here over the past eight years and turning them into products that we can commercialize.” Nanogen will be a leader in making routine clinical molecular diagnostics, he believes; it’s just a matter of selling.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.